SIRT7 and p53 interaction in embryonic development and tumorigenesis


Por: Vazquez, BN, Fernandez-Duran, I, Hernandez, Y, Tarighi, S, Thackray, JK, Espinosa-Alcantud, M, Kumari, P, Ianni, A, Cesaire, L, Braun, T, Esteller, M, Tischfield, J, Vaquero, A and Serrano, L

Publicada: 3 ene 2024
Resumen:
p53 is a hallmark tumor suppressor due in part to its role in cell cycle progression, DNA damage repair, and cellular apoptosis; its protein activity interrelates with the Sirtuin family of proteins, major regulators of the cellular response to metabolic, oxidative, and genotoxic stress. In the recent years, mammalian Sirtuin 7 (SIRT7) has emerged as a pivotal regulator of p53, fine-tuning its activity in a context dependent manner. SIRT7 is frequently overexpressed in human cancer, yet its precise role in tumorigenesis and whether it involves p53 regulation is insufficiently understood. Depletion of SIRT7 in mice results in impaired embryo development and premature aging. While p53 activity has been suggested to contribute to tissue specific dysfunction in adult Sirt7-/- mice, whether this also applies during development is currently unknown. By generating SIRT7 and p53 double-knockout mice, here we show that the demise of SIRT7-deficient embryos is not the result of p53 activity. Notably, although SIRT7 is commonly considered an oncogene, SIRT7 haploinsufficiency increases tumorigenesis in p53 knockout mice. Remarkably, in specific human tumors harboring p53 mutation, we identified that SIRT7 low expression correlates with poor patient prognosis. Transcriptomic analysis unveils a previously unrecognized interplay between SIRT7 and p53 in epithelial-to-mesenchymal transition (EMT) and extracellular matrix regulation with major implications for our understanding of embryonic development and tumor progression.

Filiaciones:
:
 Josep Carreras Leukaemia Res Inst IJC, Chromatin Biol Lab, Badalona, Spain

 Univ Autonoma Barcelona UAB, Dept Biol Cellular Fisiol & Immunol, Unitat Citol & Histol, Cerdanyola Del Valles, Barcelona, Spain

:
 Josep Carreras Leukaemia Res Inst IJC, Chromatin Biol Lab, Badalona, Spain

Hernandez, Y:
 Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ USA

Tarighi, S:
 Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, Bad Nauheim, Germany

Thackray, JK:
 Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ USA

:
 Josep Carreras Leukaemia Res Inst IJC, Chromatin Biol Lab, Badalona, Spain

Kumari, P:
 Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, Bad Nauheim, Germany

Ianni, A:
 Josep Carreras Leukaemia Res Inst IJC, Chromatin Biol Lab, Badalona, Spain

 Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, Bad Nauheim, Germany

Cesaire, L:
 City Univ New York CUNY, Borough Manhattan Community Coll BMCC, Dept Sci, New York, NY 10007 USA

Braun, T:
 Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, Bad Nauheim, Germany

:
 Josep Carreras Leukaemia Res Inst IJC, Canc Epigenet Grp, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain

 Univ Barcelona UB, Sch Med & Hlth Sci, Dept Physiol Sci, Barcelona, Catalonia, Spain

Tischfield, J:
 Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ USA

:
 Josep Carreras Leukaemia Res Inst IJC, Chromatin Biol Lab, Badalona, Spain

Serrano, L:
 City Univ New York CUNY, Borough Manhattan Community Coll BMCC, Dept Sci, New York, NY 10007 USA
ISSN: 2296634X





Frontiers in Cell and Developmental Biology
Editorial
Frontiers Media S.A., AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 11 Número:
Páginas:
WOS Id: 001147212400001
ID de PubMed: 38234684
imagen gold, Green Published

MÉTRICAS